Graves' disease and hyperthyroidism: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• IGF1R 3
• IL-6 0
• PD-1 0
• CTLA-4 0
• mTOR 0
• IL-17 0
• NRF2 0
• TP53 0
• AKT 0
• CD19 2
• ERK 0
• IL-4 0
• PD-L1 0
• PPAR 0
• SGLT2 0
• TNF 0
• BCMA 1
• BRAF 0
• CCR5 0
• CD40 0
• CTNNB1 0
• EGFR 0
• FTO 0
• GLP-1 0
• HIF-1 0
• IL-1 0
• IL-15 0
• JAK 1
• KEAP1 0
• MAPK 0
• METTL3 0
• PCSK9 0
• PI3K 0
• RANKL 0
• RAS 0
• STAT3 0
• TERT 0
• TIGIT 0
• TLR4 0

24 of 521 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIA · R43

  Development and Performance Evaluation of a TruE2 Diagnostic Algorithm for Free Estradiol

  Xyone Therapeutics Inc.· Weston, United States· US$396,322 awarded in fiscal year 2026· until Sept 2027

• NIH NIA · R01

  Discontinuation of low dose levothyroxine therapy for older adults with subclinical hypothyroidism: a randomized, double-blinded, placebo-controlled study

  Biomedical Research Fdn/Central Arkansas· Little Rock, United States· US$720,513 awarded in fiscal year 2026· until Jul 2031

• NIH NIAAA · F30

  Uncovering the role of thyroid hormone-mediated chromatin remodeling in murine ethanol consumption

  Oregon Health & Science University· Portland, United States· US$55,114 awarded in fiscal year 2026· until Jun 2029

• NIH NICHD · U01

  Advancing the Lives & HeaLth of Youth and Young Adults with Down Syndrome (ALLY-DS)

  Children's Hosp of Philadelphia· Philadelphia, United States· US$2,008,376 awarded in fiscal year 2026· until May 2029

• NIH NICHD · R21

  Atlas-based Machine Learning for Pediatric Bone Age Assessment

  University of Miami Coral Gables· Coral Gables, United States· US$395,006 awarded in fiscal year 2026· until May 2028

• European Commission (Horizon Europe) · HORIZON-CSA

  Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence (InnoThyroGen)

  Sveuciliste U Splitu Medicinski Fakultet· Split, Croatia· EU contribution €4,937,275· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

6 of 15 running projects, newest first. Listed amounts together: US$6.8m + €4.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Personalized Treatment in Thyroid Disorders

  NCT03517579· Johns Hopkins University· Updated 22 Oct 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Terminated

  Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease

  NCT05678374· Vastra Gotaland Region· Updated 14 Sept 2026

  “We had initially planned to include 60 participants per group. However, due to substantial difficulties with participant recruitment, we decided to close the study after enrolling 39, 15, and 40 participants in the respective groups.”Registry text, quoted unchanged. Source

• Withdrawn

  The Sequestration of Holistic Stress Management Techniques for Adults

  NCT06098755· Goddess Zena I. Jones· Updated 4 Feb 2026

  “No Participants Enrolled”Registry text, quoted unchanged. Source

• Withdrawn

  Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery

  NCT05774535· Istituto Auxologico Italiano· Updated 2 Oct 2025

  “No enrollment”Registry text, quoted unchanged. Source

• Terminated

  Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules

  NCT05142904· Rijnstate Hospital· Updated 17 Jul 2025

  “Switched from RCT to observational prospective cohort due to termination of subsidy (delay due to insufficient inclusion-rate). Follow-up of RCT-arm will be completed. Patients can still be included in a observational cohort.”Registry text, quoted unchanged. Source

• Suspended

  Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz

  NCT06240455· Worg Biotherapeutics Inc.· Updated 8 May 2025

  “Not feasible to recruit suitable subjects”Registry text, quoted unchanged. Source

• Terminated

  Efficacy of Methimazole Dosing Algorithm

  NCT05964452· Cook County Health· Updated 27 Dec 2024

  “Unable to reach recruiting goals”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

  NCT07722546· Biogen· Source

• Hydroxychloroquine in Mild Graves' Orbitopathy

  NCT05126147· National Taiwan University Hospital· Source

• A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

  NCT06984627· Sanofi· Source

• Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease

  NCT07369063· Northwell Health· Source

• Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)

  NCT07861152· Regeneron Pharmaceuticals· Source

• A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

  NCT06401044· Amgen· Source

• An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

  NCT07438405· Amgen· Source

• A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease

  NCT06248619· Amgen· Source

• Rubus Sanctus (Wild Blackberry) Root Extract as a Dietary Supplement for Graves' Disease

  NCT07164079· Betul Uner· Source

• In Vivo CAR-T for Refractory Graves' Disease

  NCT07333677· Shanghai Zhongshan Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• Organoids 1
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 1
• Gene Expression Profiling 14
• Sequence Analysis, RNA 2
• Proteomics 3
• Metabolomics 9
• Mass Spectrometry 5
• Flow Cytometry 3
• Immunohistochemistry 7
• Positron-Emission Tomography 2
• Magnetic Resonance Imaging 49
• Machine Learning 15
• Deep Learning 5
• Cohort Studies 69
• Genome-Wide Association Study 25

• Integrated 18F-NOTA-FAPI-04 PET/MRI for quantitative assessment of disease activity in thyroid-associated ophthalmopathy.

  Eur J Nucl Med Mol Imaging, Aug 2026

• Effect of a Limited Iodine Diet on Iodine Uptake by Thyroid Glands in Hyperthyroid Cats.

  J Vet Intern Med, Aug 2015

See which targets of this disease your abstract mentions, and go to the people working on them.